Uterine Fibroids


Up to $1,540


Uterine Fibroids: Primrose Study

Official Title

Primrose Study

Study Summary

The primary objective of this study is to demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.

Eligibility and Recruitment Information

Recruitment Status Recruiting
Eligible Genders Female
Eligible Ages 18-100
Inclusion Recalls having experienced abnormal heavy menstrual bleeding (heavy or lastingmore than 5 days) in a majority of menstrual periods over the last 6 months ; Diagnosed with uterine fibroids.
Exclusion Condition is so sever that she will require surgery within 6 months regardless of treatments provided.
Start Date
Compensation Up to $1,540 USD
Location Orlando, FL

Study Information

Condition Uterine Fibroids
Study Phase Phase 3

Administrative Information

Study ID NCT03070899
Investigators Judith White, MD

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.